Product Code: ETC6184773 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In Australia, the market for medical imaging agents, including contrast media and radiopharmaceuticals, is growing in line with the rising number of diagnostic imaging procedures such as MRI, CT scans, and PET scans. These agents improve image quality and assist in accurate disease detection. Increasing cases of chronic diseases and cancer, coupled with the aging population, are significant drivers of demand for high-quality imaging agents.
The market for medical imaging agents in Australia is growing due to a rise in chronic diseases such as cancer and cardiovascular conditions, which require frequent diagnostic imaging. Innovations in targeted contrast agents and radiopharmaceuticals are improving image quality and patient safety. Regulatory support for novel agent approvals is encouraging the development and local availability of advanced imaging compounds.
A significant challenge in the medical imaging agents market in Australia is the stringent regulatory environment governing the approval and use of contrast media and radiopharmaceuticals. These agents must meet rigorous safety and efficacy standards, which can delay product launches. Additionally, fluctuations in the global supply chain of raw materials, combined with the short shelf life of certain agents, pose logistical difficulties in maintaining consistent inventory levels across diagnostic centers.
The medical imaging agents market in Australia offers lucrative investment opportunities in the development and commercialization of next-generation contrast agents and radiopharmaceuticals. Companies that focus on targeted imaging agents, particularly for oncology and cardiovascular imaging, are likely to see strong demand. Investing in the research and development of innovative imaging agents, especially those that reduce side effects or improve image quality, can yield high returns as healthcare providers look to enhance diagnostic accuracy and patient outcomes.
Medical imaging agents are closely regulated by the TGA, ensuring safety and efficacy before clinical use. While this regulatory oversight ensures public safety, it can also slow down the introduction of new contrast agents or radiotracers. Import and usage policies for radiopharmaceuticals are further constrained by Australia`s nuclear regulatory framework, overseen by ARPANSA (Australian Radiation Protection and Nuclear Safety Agency). Additionally, high compliance costs and delays in updating the Pharmaceutical Benefits Scheme (PBS) can limit access to newer agents in the public healthcare system.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Medical Imaging Agents Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Medical Imaging Agents Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Medical Imaging Agents Market - Industry Life Cycle |
3.4 Australia Medical Imaging Agents Market - Porter's Five Forces |
3.5 Australia Medical Imaging Agents Market Revenues & Volume Share, By Isotope, 2021 & 2031F |
3.6 Australia Medical Imaging Agents Market Revenues & Volume Share, By Modality, 2021 & 2031F |
3.7 Australia Medical Imaging Agents Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Australia Medical Imaging Agents Market Revenues & Volume Share, By End Users, 2021 & 2031F |
4 Australia Medical Imaging Agents Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Medical Imaging Agents Market Trends |
6 Australia Medical Imaging Agents Market, By Types |
6.1 Australia Medical Imaging Agents Market, By Isotope |
6.1.1 Overview and Analysis |
6.1.2 Australia Medical Imaging Agents Market Revenues & Volume, By Isotope, 2021- 2031F |
6.1.3 Australia Medical Imaging Agents Market Revenues & Volume, By Technetium, 2021- 2031F |
6.1.4 Australia Medical Imaging Agents Market Revenues & Volume, By Thallium, 2021- 2031F |
6.1.5 Australia Medical Imaging Agents Market Revenues & Volume, By Gallium, 2021- 2031F |
6.1.6 Australia Medical Imaging Agents Market Revenues & Volume, By Iodine, 2021- 2031F |
6.1.7 Australia Medical Imaging Agents Market Revenues & Volume, By Samarium, 2021- 2031F |
6.1.8 Australia Medical Imaging Agents Market Revenues & Volume, By Rhenium, 2021- 2031F |
6.1.9 Australia Medical Imaging Agents Market Revenues & Volume, By Gallium, 2021- 2031F |
6.1.10 Australia Medical Imaging Agents Market Revenues & Volume, By Gallium, 2021- 2031F |
6.2 Australia Medical Imaging Agents Market, By Modality |
6.2.1 Overview and Analysis |
6.2.2 Australia Medical Imaging Agents Market Revenues & Volume, By X-Ray/CT, 2021- 2031F |
6.2.3 Australia Medical Imaging Agents Market Revenues & Volume, By MRI, 2021- 2031F |
6.2.4 Australia Medical Imaging Agents Market Revenues & Volume, By Ultrasound, 2021- 2031F |
6.2.5 Australia Medical Imaging Agents Market Revenues & Volume, By SPECT, 2021- 2031F |
6.2.6 Australia Medical Imaging Agents Market Revenues & Volume, By PET, 2021- 2031F |
6.3 Australia Medical Imaging Agents Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Australia Medical Imaging Agents Market Revenues & Volume, By Cardiology, 2021- 2031F |
6.3.3 Australia Medical Imaging Agents Market Revenues & Volume, By Cancer, 2021- 2031F |
6.3.4 Australia Medical Imaging Agents Market Revenues & Volume, By Gastrointestinal, 2021- 2031F |
6.3.5 Australia Medical Imaging Agents Market Revenues & Volume, By Musculoskeletal, 2021- 2031F |
6.3.6 Australia Medical Imaging Agents Market Revenues & Volume, By Neurology, 2021- 2031F |
6.3.7 Australia Medical Imaging Agents Market Revenues & Volume, By Nephrology, 2021- 2031F |
6.3.8 Australia Medical Imaging Agents Market Revenues & Volume, By Pulmonary, 2021- 2031F |
6.3.9 Australia Medical Imaging Agents Market Revenues & Volume, By Pulmonary, 2021- 2031F |
6.4 Australia Medical Imaging Agents Market, By End Users |
6.4.1 Overview and Analysis |
6.4.2 Australia Medical Imaging Agents Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
6.4.3 Australia Medical Imaging Agents Market Revenues & Volume, By Diagnostic Centers, 2021- 2031F |
6.4.4 Australia Medical Imaging Agents Market Revenues & Volume, By Academic Institutes and Research Organizations, 2021- 2031F |
7 Australia Medical Imaging Agents Market Import-Export Trade Statistics |
7.1 Australia Medical Imaging Agents Market Export to Major Countries |
7.2 Australia Medical Imaging Agents Market Imports from Major Countries |
8 Australia Medical Imaging Agents Market Key Performance Indicators |
9 Australia Medical Imaging Agents Market - Opportunity Assessment |
9.1 Australia Medical Imaging Agents Market Opportunity Assessment, By Isotope, 2021 & 2031F |
9.2 Australia Medical Imaging Agents Market Opportunity Assessment, By Modality, 2021 & 2031F |
9.3 Australia Medical Imaging Agents Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Australia Medical Imaging Agents Market Opportunity Assessment, By End Users, 2021 & 2031F |
10 Australia Medical Imaging Agents Market - Competitive Landscape |
10.1 Australia Medical Imaging Agents Market Revenue Share, By Companies, 2024 |
10.2 Australia Medical Imaging Agents Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |